Veradermics Names Reid Waldman as Chief Executive Officer
PUBLIC · MANEDec 11, 2024
Company
VeraDermics
West HartfordHealthcareHealth Care
Description
Veradermics announced the closing of a $75 million Series B financing, led by Suvretta Capital Management and Longitude Capital. The financing will be used to fund the ongoing pivotal clinical development of Veradermics’ lead candidate VDPHL01 for the treatment of androgenetic alopecia (AGA) or pattern hair loss (PHL).
Who to call at VeraDermics, and when
A new leader at VeraDermics brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day VeraDermics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at VeraDermics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at VeraDermics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
VeraDermics
Location
West Hartford, Connecticut, United States
About
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on turning everyday dermatology and aesthetics problems into clear, proven care.
We are on a mission to make long-ignored dermatology and aesthetics conditions simple, replacing false hope, confusion, and questionable results with solutions that people and providers can trust.
Our lead investigational product has the potential to be the first non-hormonal oral therapeutic for hair regrowth in women and men. Pattern hair loss, also known as androgenetic alopecia, is the largest aesthetics condition worldwide, with no new approved prescription therapies in nearly 30 years.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment VeraDermics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
West HartfordHealthcareHealth Care